Skunkvine

Skunkvine (Paederia foetida L.): A Comprehensive Reference

1. Identity and Botanical Profile

1.1 Nomenclature and Taxonomy

Paederia foetida, commonly known as skunkvine or Chinese fever vine, is a perennial climbing plant from the Rubiaceae family, native to Southeast Asia and also profusely available in India. The woody vine gained its name from its "foul smelling" odor when crushed, hence the origin foetida. The smell comes from sulfur-containing compounds present in the vine's leaves.

It is locally known as "Gandhavadulia" or "GandhaPrasarini," with the English name "skunkvine," and belongs to the family Rubiaceae. Additional Ayurvedic synonyms in Sanskrit include gandhaprasarini, gandhaprasarani, prasarani, sarani, bhadraparni, rajabala, pratanini, bhadra, bala, and katambhara. In Indonesia it is known as Daun Kentut or Kasembukan. Accepted taxonomic synonyms include Paederia chinensis Hance, Paederia scandens (Lour.) Merr., Paederia tomentosa Blume, and Apocynum foetium Burm.

1.2 Morphological Description

The plant is a fast-growing, slender, perennial herb. It is a climbing plant producing stems 1.5–7 meters long that take the support of other plants to grow. It lacks thorns but makes up for this with its extensive growth. It can grow up to 30 feet into tree canopies or along the ground, always twining to the right. Leaf blades are arranged opposite and have cordate bases, pointed tips, and an entire margin. Although uncommon, leaves may be found arranged in whorls. Flowers are lilac with red centers and are small in size. Fruits are also small, shiny, brown, and spherical, containing two seeds.

The plant can be found flowering and fruiting throughout the year in tropical and subtropical conditions; in other localities, it flowers during the rainy season and fruits early in the dry season.

1.3 Natural Distribution

Paederia foetida is a widespread plant of the Rubiaceae family distributed in temperate and tropical Asia. P. foetida grows mainly in China, Bangladesh, India, and Mauritius. The plant is currently on the Florida Noxious Weed List and on the Florida Exotic Pest Plant Council's Category I list of invasive plants. Native to Eastern and southern Asia, the vine was introduced to Hernando, Florida in 1897 with a prospect as a fiber crop. It expanded beyond its intended purpose and invaded natural areas, becoming a nuisance in central and north-central Florida.

1.4 Common Preparations and Dosage Forms

Paederia foetida has a long-standing role in Ayurvedic, Unani, and traditional Southeast Asian medicine. In Ayurveda, the herb is especially used for treating rheumatic disorders and vata imbalances. Classical Ayurvedic texts recommend it in formulas for joint stiffness, nerve pain, and paralysis, often in the form of medicated oils, powders, or decoctions.

The decoction of the whole plant is traditionally used in Ayurvedic medicine for the treatment of various diseases. Well-known classical Ayurvedic formulations derived from this drug include Prasarinyadi Taila and Prasarinyadi Kashaya. The plant also enters into the preparation of Dasmularishta. In contemporary contexts, the plant is processed into dry powdered extracts for nutraceutical blending. Its different parts are used in different Ayurvedic preparations; its leaves are used against herpes infection, while roots are used for relieving pain in the chest or liver and inflammation of the spleen, and are also used as an emetic.

Ayurvedic sources report the following preparation methods: decoction (kashaya): one tablespoon of powder added with two cups of water, boiled and reduced to one cup, then filtered. In northeastern India, the tender leaves are boiled and eaten with chili and salt.

---

2. Traditional and Historical Use

2.1 Ayurvedic System (India)

The plant has a long history of usage in Chinese, Ayurvedic, and other traditional systems of medicine for numerous ailments. In Ayurveda, it is considered as alterative, antiarthritic, antispasmodic, diaphoretic, expectorant, and stomachic. It is also used in asthma, bowel complaints, diarrhea, diabetes, and seminal weakness. Ayurvedic texts report its use for arthritis, vesical calculi, inflammation, asthma, diarrhea, dysentery, piles, diabetes, seminal weakness, and a variety of other ailments.

Notable Ayurvedic medicines include Prasarini Thailam, used in arthritis and sciatica. According to Ayurvedic principles, the herb decreases Kapha and Vata doshas, thereby restoring proper function of the body.

2.2 Traditional Chinese Medicine

Known by the local name Jishiteng, the plant has been utilized for both medicinal and edible purposes in China for over three centuries. In Chinese traditional medicine (CTM), P. foetida has been widely used for the treatment of dyspepsia, jaundice, pains, and diarrhea, among other conditions.

2.3 Folk Medicine Across South and Southeast Asia

For centuries, it has been a staple in the folk medicine of India, China, Japan, and Southeast Asia, used for everything from arthritic pain and diarrhea to liver disease and sexual debility. In folk medicine across Bangladesh, India, Nepal, Thailand, and Indonesia, both the aerial parts and roots of the plant are employed for digestive complaints, fevers, and intestinal worms.

Among lesser-studied plants, Paederia foetida has been used by various ethnic tribes as food and medicine. Many of its therapeutic properties relate to the gastrointestinal system and suggest its potential utility for gastrointestinal ailments. Several ethnic groups throughout the world have used this plant to cure common health complaints namely abdominal pain, gastritis, dysentery, diarrhoea, constipation, and joint pain.

The plant has been utilized as food and medicine by several ethnic groups against stomach pain, bowel disease, snake bite, bone fractures, burns, and scalding.

---

3. Phytochemistry: Key Constituents

3.1 Overall Chemical Complexity

A total of 217 phytoconstituents comprised of glycosides, anthraquinones, phenolic derivatives, terpenoids, phytosterols, and other miscellaneous compounds have been catalogued in a systematic review of the plant's phytochemistry. A separate 2026 review identified 208 phytochemical constituents, including volatile oils, phenolic compounds, terpenoids and their derivatives, and fatty acids. The biologically active constituents present in P. foetida include phenolics, glycosides, alkaloids, saponins, tannins, and terpenoids.

3.2 Iridoid Glycosides

The main components of the two significant Paederia species are iridoid glycosides, such as asperuloside, paederoside, and scanderoside. These represent the most pharmacologically studied class of compounds in the plant. Asperuloside is a major iridoid glycoside with anti-inflammatory, analgesic, and diuretic properties. Paederosidic acid is an iridoid with documented hepatoprotective and anti-inflammatory effects. Paederoside is a unique iridoid found in Paederia species, contributing to the plant's overall bioactivity.

3.3 Phenolic Compounds and Flavonoids

The therapeutic effects of P. foetida are closely linked to its high levels of polyphenols, especially chlorogenic acid, isoquercetin, rutin, scopoletin, quinic acid, and quercetin. These compounds are very important for its strong antioxidant and protective effects. The total phenolic content, total flavonoid content, and IC₅₀ values show that P. foetida has a good antioxidant capacity.

3.4 Triterpenes and Phytosterols

Phytochemical analysis revealed that P. foetida is rich in lupeol, ursolic acid, and beta-sitosterol. β-Sitosterol has a variety of pharmacological properties, with analgesic, immunomodulatory, antiseptic, antineoplastic, anti-inflammatory, cholesterol-decreasing, hepatoprotective, antioxidant, and anti-diabetic activity. Ursolic acid is a pentacyclic triterpene with anti-inflammatory, anticancer, hepatoprotective, and antimicrobial properties. Ellagic acid is a phenolic compound with antioxidant, anticancer, and anti-inflammatory effects. β-Sitosterol, stigmasterol, and campesterol are plant sterols with anti-inflammatory, cholesterol-lowering, and immunomodulatory activities. Epifriedelinol is a triterpenoid with documented anti-inflammatory properties.

3.5 Volatile Oils and Other Constituents

The plant also contains a variety of phytochemicals such as asperuloside, paederosidic acid, sitosterols, campesterol, lignans, alkaloids, volatile oils, iridoids, methylindooxy substances, stigmasterol, tannins, triterpenoids, ellagic acid, ursolic acid, epifriedelinol, and phenolic compounds. Quantitative phytochemical analysis of the plant further indicates the presence of methyl-mercaptan, phenolics, a high percentage of minerals, ursolic acid, β-sitosterol, oleanolic acid, and arachidic acid. From a phytochemical perspective, P. foetida is known to contain a diverse spectrum of secondary metabolites, including iridoid glycosides, pyrone compounds, flavonoids, terpenoids (including diterpenoids), as well as a lipid fraction consisting of fatty acids and fatty acid esters.

---

4. Mechanisms of Action

4.1 Anti-inflammatory Mechanisms

Studies show that P. foetida suppresses prostaglandin E2 (PGE2) and cyclooxygenase-2 (COX-2) expression via inhibition of the nuclear factor-κB (NF-κB) pathway. It also reduces the pro-inflammatory cytokines TNF-α, IL-1β, and IL-2. This multi-target suppression of inflammatory mediators has been explored at a molecular level. Molecular docking results have revealed that several phytochemical compounds exhibit favorable binding energies and stable interaction patterns with key amino acid residues of NF-κB p65, such as Lys221, Arg246, Ser276, and Glu279. Among tested compounds, quercetin and asperuloside demonstrated strong binding affinity and multiple hydrogen bonds within the transcriptionally active region of NF-κB p65.

Asperuloside and asperulosidic acid significantly decreased the production of nitric oxide (NO), PGE₂, TNF-α, and interleukin-6 (IL-6), in parallel with the inhibition of iNOS, COX-2, TNF-α, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.

A detailed investigation of the butanol fraction of a methanol extract (BMEL) of the defatted leaves demonstrated that this fraction produced a significant inhibition of granulation tissue formation in cotton-pellet-implanted rats. It decreased liver aspartate transaminase activity without affecting serum aspartate transaminase activity. It did not affect adrenal weight and ascorbic acid content significantly, thus ruling out a stimulation of the adrenal-pituitary axis. BMEL antagonized hyposaline-induced hemolysis of human red blood cells and elevation of rat serum acid phosphatase activity, indicating the presence of membrane-stabilizing activity. It also inhibited the elevation of serum orosomucoid levels in rats, suggesting the possibility of disease-modifying antirheumatic activity.

4.2 Antioxidant Mechanisms

The chlorogenic acid and quercetin content shields hepatocytes and renal cells from toxin-induced damage by enhancing endogenous antioxidant enzymes (SOD, GPx) and reducing oxidative stress. This validates the traditional use in liver disorders and supports its safety profile. Fresh P. foetida has demonstrated the highest antioxidant activity at 78.1%, which is comparable to DL-tocopherol (79.7%).

4.3 Antidiabetic Mechanisms

Studies evaluating the enzymatic inhibition activity of P. foetida twig extracts found that three different twig extracts — hexane (PFH), chloroform (PFC), and methanol (PFM) — were screened for their α-amylase and α-glucosidase inhibition potential. Results revealed the presence of 12 bioactive compounds responsible for the inhibitory activity, including dl-α-tocopherol, n-hexadecanoic acid, stigmastanol, stigmasterol, and α-monostearin. The study provides informative data on the potential antidiabetic inhibitors identified in P. foetida twigs, indicating the plant has therapeutic effect properties to manage diabetes.

4.4 Antidiarrheal Mechanisms

Results from animal studies suggest that Paederia foetida shows antidiarrheal activity by inhibiting intestinal motility, which justifies its use in traditional medicine. The extract significantly decreased cisplatin-induced gastrointestinal motility at all doses at both time intervals and also enhanced the morphine-induced reduction of motility at the 500 mg/kg dose level.

---

5. Scientific Evidence by Area of Use

5.1 Anti-inflammatory and Analgesic Activity

Evidence Level: Predominantly preclinical (animal and in vitro); one limited clinical report in rheumatic disease patients.

In vivo anti-inflammatory effects of P. foetida were demonstrated in rats, evaluating it against a variety of phlogistic agents as well as turpentine oil, prostaglandin, and arachidonic acid. Groups included a normal control, a PF-only group at 100 mg/kg, an arthritic control (CFA only), groups receiving CFA plus PF at 25, 50, and 100 mg/kg, and a reference group receiving CFA plus indomethacin at 10 mg/kg body weight.

A clinical report noted that after 42 days of clinical treatment with P. foetida, 65% of patients showed relief from joint pain, 70% from swelling, 75% from stiffness, and 70% from tenderness. The plant also lowered elevated levels of acute phase proteins and was therefore suggested as a potential disease-modifying anti-rheumatic drug (DMARD) offering advantages over NSAIDs, as the latter do not affect these proteins. This clinical report is limited and has not been confirmed in large-scale randomized controlled trials. Bioguided isolation of active constituents responsible for the medical uses, as well as study of their structure–activity relationship and modes of action, is urgently needed.

5.2 Antidiarrheal Activity

Evidence Level: Preclinical (animal); traditional use corroborated by in vivo mouse models.

P. foetida is used as a remedy for diarrhea and dysentery in Asia. Antidiarrheal activity of a 90% ethanol extract of P. foetida was investigated using castor oil and magnesium sulphate-induced diarrhea models in mice. The extract significantly increased the latent period of diarrhea in both models. All evidence in this area to date is from in vitro or animal models; no human randomized trials have been published.

5.3 Antidiabetic Activity

Evidence Level: Preclinical (in vitro, in silico, and animal); no clinical human trials identified.

There is general clinical understanding that reactive oxygen species (ROS) capable of oxidizing cellular proteins, nucleic acids, and lipids increase in patients with diabetes, and that the onset of diabetes is closely associated with oxidative stress through oxidation, nonenzymatic protein glycation, and oxidative degradation of glycated proteins. P. foetida's antioxidant phytochemicals and its demonstrated α-amylase and α-glucosidase inhibition in vitro suggest a plausible antidiabetic mechanism, but clinical validation in humans is absent from the published literature.

5.4 Hepatoprotective Activity

Evidence Level: Preclinical (in vitro hepatocytes and rat models); no human trials identified.

The hepatoprotective activity of a methanolic extract of P. foetida was tested on newly separated rat hepatocytes and animals intoxicated with CCl₄. In a dose-dependent manner, the results revealed substantial hepatoprotection. Analytical studies based on GC–MS and LC–MS have confirmed that volatile and semi-volatile components of P. foetida leaves dominated by lipids and terpenoids contribute to the reported hepatoprotective effects.

5.5 Antinociceptive (Pain-Relieving) Activity

Evidence Level: Preclinical (animal — rodent models); no standalone human clinical analgesic trials identified for this plant alone.

Phytochemical studies revealed that iridoids, flavonoids, volatile oil, and other metabolites in the two main Paederia species possess versatile bioactivities including antinociceptive activity. An injection developed from the related species P. scandens has been clinically used as an analgesic drug. Evidence for P. foetida specifically as an analgesic in humans remains in the preclinical stage.

A methanolic extract of leaves of P. foetida was administered orally to Swiss albino mice at doses of 100, 200, and 400 mg/kg for 1, 7, or 14 days. All doses revealed a significant reduction (P ≤ 0.01) in immobility time in a dose-dependent manner in tail suspension and forced swimming tests. A significant increase in locomotor activity (P ≤ 0.01) was observed at all dose levels. The extract at 400 mg/kg revealed the greatest reduction in immobility time in both tests.

5.6 Antitussive Activity

Evidence Level: Preclinical (animal — non-anesthetized cats); no human clinical trials identified.

Nosáľová and colleagues (2007) investigated the antitussive activity of the ethanolic extract of Paederia foetida (Rubiaceae family) in non-anesthetized cats. This animal-model study is the primary published evidence for antitussive effects; human data are lacking.

5.7 Antimicrobial Activity

Evidence Level: In vitro only.

Paederia foetida is particularly valued for its ability to treat gastrointestinal disorders such as diarrhea and dysentery, owing to its potent antibacterial and anti-inflammatory effects. Antimicrobial assessments have been conducted exclusively in cell-based assays. No clinical antimicrobial trials in human patients have been published.

5.8 Anthelmintic Activity

Evidence Level: In vitro (worm models).

The methanolic extract of the leaves of Paederia foetida was screened for anthelmintic activity against Pheretima posthuma and Tubifex tubifex. All evidence is in vitro; clinical anthelmintic trials in humans have not been reported.

5.9 Gastroprotective Activity

Evidence Level: Preclinical (animal models).

P. foetida is promising as a remedy for lifestyle-related conditions, especially treatment of ulcers. In a rat model study, the methanol extract of Paederia was found to contain active gastroprotective constituents that effectively antagonized gastric ulcerogenic mechanisms, indicating an anti-secretory mechanism.

5.10 Spermatogenic and Male Reproductive Effects

Evidence Level: Preclinical (animal — rat models); no human clinical data.

Mounting data on numerous active ingredients have indicated that they may be beneficial for spermatogenesis, wound healing, inflammatory illnesses, and cancer. Histological evaluation of the testes from treatment and control groups in a rat study revealed that the extract and testosterone substantially influenced spermatogenesis. Human clinical trials have not been published.

5.11 Neurological and Cognitive Effects

Evidence Level: Emerging preclinical (animal models); no human clinical data.

Scopolamine-induced dementia that mimicked Alzheimer's disease was considerably alleviated by pretreatment with 1,000 mg/kg P. foetida leaf extract in a rat model. This is a preliminary preclinical finding, and no human trials in cognitive decline have been published. Additionally, the iridoid asperuloside, which is found in P. foetida, has demonstrated promise as a neuroprotective agent by modulating key signaling pathways, including restoring mitochondrial function and promoting neuronal survival.

5.12 Anticancer Activity

Evidence Level: Preliminary (in vitro / cytotoxicity assays); no human trials.

Growing evidence shows many of the plant's active constituents to be effective in cancer, inflammatory diseases, wound healing, and spermatogenesis. Phytochemical analysis revealed that P. foetida is rich in lupeol, ursolic acid, and beta-sitosterol, which are shown to have anticancer activities. All anticancer evidence is derived from in vitro cytotoxicity assays; no human trials have been conducted.

---

6. Body Systems and Health Areas of Association

The extracts, essential oils, and compounds isolated from P. foetida exhibit a broad spectrum of biological and pharmacological activities, including analgesic, anti-inflammatory, anti-arthritic, antimicrobial, hepatoprotective, anti-diabetic, antioxidant, gastrointestinal, antihyperuricemic, anthelmintic, cytotoxic, renoprotective, cardiotonic, wound healing, sedative, anxiolytic, and anticonvulsant properties.

• Musculoskeletal System: The plant is mainly used for arthritis and rheumatic disorders.
• Gastrointestinal System: Many of its therapeutic properties relate to the gastrointestinal system, suggesting its potential utility for gastrointestinal ailments.
• Hepatic and Renal Systems: Bioactive components are associated with hepatorenal protective pharmacological properties.
• Endocrine/Metabolic System: Paederia foetida demonstrates diverse biological activities including blood glucose-lowering effects.
• Respiratory System: The plant is also used in asthma and bowel complaints.
• Nervous System: Animal studies suggest sedative, anxiolytic, anticonvulsant, and potential cognitive-protective properties, all at a preclinical stage.
• Reproductive System: Mounting data indicate potential benefits for spermatogenesis.
• Integumentary System (skin): The plant's bioactive components are associated with antimicrobial activity and wound healing potential, studied primarily in vitro.

---

7. Reported Dosages in Studies

The following dosage information is drawn exclusively from the published research literature and should not be interpreted as dosage recommendations.

• In the adjuvant-induced arthritis rat model, P. foetida was administered at 25, 50, and 100 mg/kg body weight, compared against indomethacin at 10 mg/kg body weight.
• In antinociceptive / behavioral mouse studies, the methanolic leaf extract was administered orally at 100, 200, and 400 mg/kg for 1, 7, or 14 days.
• In an intestinal motility study, the extract enhanced morphine-induced reduction of motility at a 500 mg/kg dose level.
• In a sub-chronic (8-week) rat toxicity study, male Wistar rats were gavaged daily with 0–1,000 mg/kg BW of P. foetida extract.
• In a cognitive impairment model in rats, pretreatment was given at 1,000 mg/kg of P. foetida leaf extract.

In the Ayurvedic tradition, non-research sources report powders at 1–3 grams twice daily and decoctions at 50–100 mL once or twice daily, but these figures are not derived from controlled clinical trials and are characteristic of traditional practice only.

---

8. Safety Profile and Toxicology

8.1 Acute Toxicity

P. foetida methanol extract (PFME) exhibited a favorable safety profile, with no adverse effects detected at doses up to 2,000 mg/kg in acute toxicity studies and 1,000 mg/kg/day in sub-acute toxicity studies, thereby establishing this dosage as the No-Observed-Adverse-Effect Level (NOAEL). The LD₅₀ of PF methanol extract in both male and female rats was greater than 2,000 mg/kg. Hepato-renal damages were noted in both sexes at 1,500 mg/kg of PF methanol extract. The NOAEL of PFME was established at ≤1,000 mg/kg in male and female rats.

8.2 Sub-chronic Toxicity and Hepatic Effects

In an 8-week rat study, the liver weight of rats treated with 1,000 mg/kg BW was increased compared to the control group. Liver and kidney histopathology showed no difference between groups. Markers of liver damage (alanine aminotransferase and aspartate aminotransferase) and kidney damage (blood urea nitrogen and creatinine) showed no change between all groups.

8.3 Cytochrome P450 Drug–Herb Interactions

This is the most significant and well-documented safety signal for P. foetida. The purpose of one published investigation was specifically to examine the inhibitory potential of the P. foetida ethanolic extract and its bioactive constituent lupeol on hepatic phase I drug-metabolizing enzymes, using rat liver microsomes (RLMs) and individual CYP isozymes (CYP3A4 and CYP2D6).

Subchronic exposure to the extract significantly reduced Cyp3a1, Cyp2d1, and Cyp2c6 expressions in rat livers in a dose-dependent manner, without toxicity or change in histology and biochemical data. However, its concomitant use with prescription drugs needs further investigation.

Long-term oral administration of Paederia foetida decreases cytochrome P450 mRNA expression in rat models. The clinical significance of this CYP450 downregulation for drug metabolism in humans is not yet established, but the finding raises a theoretically meaningful concern for individuals taking pharmaceutical drugs metabolized by CYP3A4, CYP2D6, or CYP2C pathways.

8.4 General Safety Observations

Paederia foetida has long been utilized in traditional medicine, necessitating comprehensive safety assessments and precise dosage recommendations to avert potential adverse effects in human use. The existing toxicological database is entirely animal-based; no formal safety or tolerability trials in humans have been published in the peer-reviewed literature to date. Additional studies on this medicinal plant and the investigation of new counteractive medications to determine their mode of action are still needed before healthcare applications are firmly established.

---

9. Evidence Strength: An Honest Summary

The totality of pharmacological research on Paederia foetida is substantial in preclinical terms but very limited in clinical terms. Owing to its popularity in folk medicine, it has been the subject of intense pharmacological and chemical studies for the last 30 years. However, P. foetida and P. scandens have emerged as good sources of traditional medicines, and available scientific references reveal that the biological properties of these two Paederia species have been evaluated by modern pharmacological studies. However, bioguided isolation of active constituents responsible for the medical uses, as well as study of their structure–activity relationship and modes of action, is urgently needed.

• Anti-inflammatory / Antirheumatic: Mechanistic preclinical data are strong; one limited clinical report in rheumatic patients exists but has not been replicated in a randomized controlled trial.
• Antidiarrheal: Consistent preclinical evidence across multiple animal studies; traditional use is widespread; no human RCTs.
• Antidiabetic: Preliminary in vitro and in silico evidence only; no clinical trials.
• Hepatoprotective: Preclinical in vitro and rat-model data; no clinical trials.
• Antitussive: Animal model evidence in cats; no human trials.
• Anticancer / Cytotoxic: Exclusively in vitro; highly preliminary.
• Spermatogenesis: Preclinical rat data only; no human data.
• Neuroprotective / Cognitive: Very early preclinical stage; no human data.

References

• A review on phytochemistry of Paederia foetida Linn — Phytomedicine Plus, ScienceDirect (2023)
• Wang L, Jiang Y, Han T, et al. A phytochemical, pharmacological and clinical profile of Paederia foetida and P. scandens — Natural Product Communications, PubMed (2014)
• Paederia foetida Linn. inhibits adjuvant induced arthritis by suppression of PGE2 and COX-2 expression via nuclear factor-κB — Food & Function, RSC Publishing (2015)
• Paederia foetida Linn. inhibits adjuvant induced arthritis by suppression of PGE(2) and COX-2 expression via nuclear factor-κB — PubMed (2015)
• Comparative study of the antidiabetic potential of Paederia foetida twig extracts — PMC (2019)
• Identification of Antidiabetic Metabolites from Paederia foetida L. Twigs by GC-MS Metabolomics — PMC (2019)
• Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of NF-κB and MAPK Signaling Pathways — PMC (2018)
• Gastroprotective mechanism of Paederia foetida Linn. — a popular edible plant — PMC (2015)
• De S, Ravishankar B, Bhavsar GC. Investigation of the anti-inflammatory effects of Paederia foetida — Journal of Ethnopharmacology, ScienceDirect (1994)
• Acute oral toxicity and hepatic responses to Paederia foetida leaf extract in Wistar rats — ScienceDirect (2026)
• Comprehensive phytochemical characterization, antioxidant potency, and toxicological evaluation of Paederia foetida in Wistar albino rats — PubMed (2025)
• Long-term oral administration of Paederia foetida decreases cytochrome P450 mRNA expression — Journal of Applied Pharmaceutical Sciences Online
• Effects of Paederia foetida and its Bioactive Phytochemical on CYP Herb-Drug Interactions — Natural Product Communications, SAGE (2017)
• A delve into the pharmacological targets and biological mechanisms of Paederia foetida Linn. — Naunyn-Schmiedeberg's Archives of Pharmacology, Springer (2023)
• Paederia foetida — a promising ethno-medicinal tribal plant of northeastern India — Journal of Forestry Research, Springer (2013)
• A review on botany, traditional edible uses, nutritional composition, phytochemical constituents, and bioactivities of Paederia foetida L. — European Food Research and Technology, Springer (2026)
• Dwivedi J et al. Paederia foetida Linn (Rubiaceae): Chemical Diversity, Phytopharmacological Potential, Quantitative Analysis and Clinical Approaches — Current Pharmaceutical Design, Bentham Science
• Molecular Interaction Mapping of Paederia foetida Phytochemicals against NF-kB p65 — Biology, Medicine & Natural Product Chemistry (2024)
• Neuroprotective effects of paederoside against mitochondrial dysfunction in rotenone-induced cell models of Parkinson's disease — Frontiers in Neuroscience (2026)
• Paederia foetida (Skunk vine) — University of Florida Botany (2013)
• Phytochemical Compounds and Antioxidant Activity of P. foetida — UiTM Institutional Repository
• Zaman AMM et al. Bioactive components of Paederia foetida Linn. and its role in disease management — IJPSR (2023)